MA-ANTERRA-CAPITAL
29.6.2021 14:02:13 CEST | Business Wire | Press release
Anterra Capital (“Anterra”), the international food and agriculture specialist venture capital firm, today announced the initial closing of its second food and agriculture technology fund, Anterra F&A Ventures II, raising $175 million, exceeding the targeted size of the fund. Due to the positive market reception for the fund’s mission and strategy, Anterra is tracking towards an upsized second fund, and anticipates a final closing in the third quarter, 2021.
Anterra’s unique investment approach has attracted commitments from a prestigious and aligned group of long-term oriented global investors, with continued support from Eight Roads Ventures, backed by Fidelity, and Rabo Investments, the captive investment arm of the largest global food and agricultural bank out of the Netherlands - Rabobank. New investors include Novo Holdings, a leading global life sciences investor based out of Denmark; Tattarang, one of Australia’s largest private investment groups and the holding company of the Forrest family’s private business interests; as well as other well-respected family offices, sovereign wealth funds, and state-owned investors that provide a global presence, spanning across multiple continents.
Anterra’s mission is to invest in and partner with entrepreneurs transforming our vital food economy through biotech and digital innovation across crop science, animal health, and human nutrition. As a research driven, value-focused specialist investor Anterra uniquely combines a traditional venture investment approach and “venture creation,” building and scaling transformative businesses with its deep industry knowledge and vast global network as a pioneer in the space. While investor interest is growing in the Food & Ag industry, early-stage investment in this essential segment significantly trails that of other key industries, for comparison, less than half of that in Pharma & Biotech (~$40 billion) and about a fifth of venture investment in Software (~$100 billion).
“The food economy is in critical condition, and new digital and biotech solutions are desperately needed in order to support better outcomes for farmers, consumers and the environment,” said Adam Anders, Managing Partner of Anterra Capital. “With the first close, we continue our mission to sustainably transform our food economy, building on our leadership position as an early-stage investor in markets such as plant and animal health, while actively expanding our investment activity across the food and agriculture value chain.”
Daniel Auerbach, Senior Managing Partner and Global Head of Eight Roads Ventures, one of Anterra’s original lead investors, added: “Within Food & Ag, Anterra sits at the intersection of life sciences and digital technology and our expanded investment reflects our confidence in Anterra’s mission, leadership and performance for us over the past eight years.”
“We are excited to partner with Anterra and support the fund’s transformational mission, which is aligned with our investment activity across the biotech space overall, and emphasizes our commitment to investing in innovation within Food & Agriculture,” said Kartik Dharmadhikari, a Partner of Novo Growth within Novo Holdings.
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
About Eight Roads Ventures
Eight Roads Ventures is a global investment firm backed by Fidelity. Eight Roads Ventures manages $7bn of assets across its offices in China, Hong Kong, India, Japan, UK and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, AppsFlyer, BlackDuck, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, PharmEasy, Shadowfax, Toast, Wallapop, WuXi PharmaTech, and Xoom. Further information: https://eightroads.com
About Novo Holdings A/S
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk
About Rabo Investments
Rabo Investments is Rabobank’s PE investment franchise. It has invested over €1.5 billion worldwide within the cutting-edge Food & Agri, Sustainability, and Healthcare sectors in the Netherlands and within the Food & Agri sector worldwide. The investments range from growth capital for innovative start-ups and scale-ups to investments in established companies and funds. Further information: https://raboinvestments.com
About Tattarang
Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its diverse investment portfolio spans across agri-food, energy, resources, property and lifestyle. The group is made up of six business divisions including Harvest Road which is one of Australia’s largest and most diverse agricultural businesses with an expanding portfolio of high-quality foods. Further information: www.tattarang.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom